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Background: Recent data from neuroimaging, genetic and clinical trials and animal models suggest a role for altered glutamatergic
neuro transmission in the pathogenesis of obsessive–compulsive disorder (OCD). The aim of this study was to investigate whether vari-
ants in the GRIN2B gene, the gene encoding the NR2 subunit of the N-methyl-D-aspartate (NMDA) glutamate receptor, may contribute
to genetic susceptibility to OCD or to different OCD subphenotypes. Methods: Between 2003 and 2008, we performed a case–control
association study in which we genotyped 10 tag single-nucleotide polymorphisms (SNPs) in the 3′ untranslated region (3′ UTR) of
GRIN2B. We performed SNP association and haplotype analysis considering the OCD diagnosis and different OCD subphenotypes:
early-onset OCD, comorbid tic disorders and OCD clinical symptom dimensions. Results: We enrolled 225 patients with OCD and
279 controls recruited from the OCD Clinic at Bellvitge Hospital (Barcelona, Spain). No significant difference in the distribution of alleles
or genotypes was detected between patients with OCD and controls. Nonetheless, on analyzing OCD subphenotypes, the rs1805476
SNP in male patients (95% confidence interval [CI] 1.37–4.22, p = 0.002) and a 4-SNP haplotype in the whole sample (rs1805476,
rs1805501, rs1805502 and rs1805477; odds ratio 1.92, 95% CI 1.22–3.01; permutation p = 0.023) were significantly associated with the
presence of contamination obsessions and cleaning compulsions. Limitations: Study limitations included the risk of population stratifica-
tion associated with the case–control design, use of psychiatrically unscreened blood donors as the control group, reduced sample size
of participants with certain OCD subphenotypes and tested polymorphisms limited to 3′ UTR and exon 13 of GRIN2B. Conclusion: Our
results converge with recent data suggesting a possible contribution of glutamatergic variants to the genetic vulnerability to OCD or at
least to certain OCD manifestations. The dissection of OCD into more homogeneous subphenotypes may constitute a useful tool to dis-
entangle the complex genetic basis of the disorder.
Introduction
An emerging body of evidence from neuroimaging, genetic
and clinical trials and animal models supports the hypothe-
sis that dysregulation of glutamate neurotransmission may
contribute to the pathophysiology of obsessive–compulsive
disorder (OCD).1 It has been suggested that a frontocortical
hyperglutamatergic dysfunction underlies the  cortico–
striatal– thalamo–cortical abnormalities observed in imaging
studies of OCD.2 Greater glutamatergic concentrations in
the left striatum, which normalized after 12 weeks of parox-
etine therapy, have been described in psychotropic-naive,
non depressed pediatric patients with OCD.3 Similarly, in-
creased levels of a combined measure of glutamate and glu-
tamine relative to creatine were noted in orbitofrontal white
matter in adult patients with OCD.4 In contrast, lower gluta-
matergic concentrations were observed in the anterior cin-
gulate cortex of children and adolescents with OCD5 and in
women with OCD.6 Finally, significantly higher levels of
cerebro spinal fluid glutamate have been described in
 patients with OCD.7 Animal models confirm the role of
 corticolimbic glutamatergic hyperactivation in patients
with OCD.8 In animal models, D1CT-7 transgenic mice,
which show chronic hyperactivation of orbitofrontal,
 somatosensory– sensorimotor and limbic glutamatergic out-
put neurons, engaged in OCD-like behaviours,9 and mice
with genetic deletion of SAPAP3, a post synaptic scaffolding
protein at glutamatergic synapses, exhibited a behavioural
phenotype similar to OCD with compulsive overgrooming
behaviour and increased anxiety, which improved in re-
sponse to selective serotonin reuptake inhibitors.10 Finally,
glutamatergic neurotransmission modu lating agents, such
as  riluzole, topiramate, N-acetylcysteine, memantine or 
D- cycloserine, are currently being tested in patients with
OCD and have shown some evidence of benefit in those
with treatment-resistant OCD.11
Several genetic studies have reported positive associa-
tions between glutamatergic genes and OCD. The gene that
encodes the neuronal glutamate transporter (SLC1A1) has
been the most extensively studied. A sex- specific associa-
tion between SLC1A1 and OCD in male, but not in female,
patients has been reported,12–16 although negative results
have also been published.17 Preliminary results also suggest
a possible association between OCD and genetic variations
of certain ionotropic glutamate receptors, including GRIK2
(glutamate receptor, ionotropic, kainate 2)18,19 and GRIN2B
(ionotropic glutamate receptor, N-methyl-D-aspartate sub-
unit 2B).20
Arnold and colleagues20 described a positive association
between variants in the 3′ untranslated region (3′ UTR) of the
GRIN2B gene — the gene encoding the NR2 subunit of the 
N-methyl-D-aspartate (NMDA) glutamate receptor — and
OCD in 178 affected individuals from 130 families. The
NMDA receptors (NMDAR) are ligand- and voltage-gated
ion channels, composed of heteromeric complexes containing
an obligatory NR1 (GRIN1) subunit, plus an additional NR2
(GRIN2A-D) or NR3 (GRIN3A,B) subunit.21 The NMDA re-
ceptors are critical for corticogenesis, neuronal migration and
synaptogenesis during brain development. The NR2B sub-
unit has been reported to play an essential role in memory
and learning by regulating key aspects of synaptic plasti -
city.22,23 In this sense, overexpression of GRIN2B in the mouse
forebrain has been reported to enhance hippocampal long-
term potentiation, spatial learning and memory and to im-
prove learning processes involved in fear conditioning and
extinction.24 Furthermore, NR2B receptors are highly ex-
pressed in medium spiny neurons of the striatum, neurons
that have been implicated in response control processes like
error processing and response inhibition.25 Since response in-
hibition has been proposed as an endophenotype for OCD,26
and since obsessive–compulsive symptoms improve in re-
sponse to cognitive–behaviour therapy, whose main com -
ponent — exposure — relies on the basic principles of extinc-
tion learning, we considered that the preliminary association
reported between GRIN2B and OCD deserves further study
and replication in independent samples of patients with the
disorder.
Recent models emphasize the heterogeneous nature of
OCD, a fact that partially explains the extreme difficulty in
identifying vulnerability genes for the disorder. So, exploring
OCD subphenotypes (e.g., early OCD onset, comorbid tic dis-
orders or clinical symptom dimensions), which are likely to
be more etiologically homogeneous and closely linked to the
action of genes, may help us to disentangle the complex gen -
etic basis of the disorder.27 We hypothesized that genetic vari-
ation within GRIN2B would be associated with OCD and/or
its different subphenotypes. To test this hypothesis, we per-
formed a case–control association study by geno typing
12 SNPs in exon 13 or in the 3′-untranslated region (3′ UTR)
of GRIN2B in a large sample of adult OCD probands and
healthy controls, and analyzed the possible relation between
these variants and OCD and OCD subphenotypes including
early-onset OCD, OCD with comorbid tic disorders and
 obsessive–compulsive symptom  dimensions.
Methods
Participants
We recruited participants from the OCD Clinic at Bellvitge
Hospital (Barcelona, Spain) between 2003 and 2008. To be in-
cluded in the study, patients had to fulfill DSM-IV criteria for
OCD28 for a period of at least 1 year. Diagnoses were made on
the basis of structured interviews conducted independently
by 2 trained psychiatrists (P.A. and C.S.) using the Structured
Clinical Interview for DSM-IV Axis I disorders, clinician ver-
sion (SCID-CV).29 Exclusion criteria were age younger than 18
or older than 65 years, psychoactive substance  abuse or  de-
pendence (current or in the past 6 months), psychotic disor-
ders, mental retardation and severe organic or neurologic
pathology other than tic disorder. Comorbidity with other
DSM-IV Axis I disorders was not an exclusion criterion pro-
vided that OCD was the main diagnosis and the primary rea-
son for seeking medical assistance. We recruited the control
participants from a group of healthy blood donors. They
were not psychiatrically screened.
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Written informed consent was obtained from each partici-
pant after a full description of the study, which was ap-
proved by the hospital’s ethics committee.
Clinical assessment included information on age at onset
of OCD, defined as the age when symptoms became a con-
siderable source of distress and interfered with the patient’s
social functioning. The threshold for early-onset OCD was es-
tablished at age 15 years. A clinician-administered version of
the Yale–Brown Obsessive–Compulsive Scale (Y-BOCS)30 and
the 21-item Hamilton Rating Scale for Depression (HAM-D)31
were used to assess the severity of obsessive–compulsive and
depressive symptoms, respectively. We used the clinician-
 administered version of the Y-BOCS Symptom Checklist30 to
ascertain the presence of 5 previously identified symptom
dimensions designated as “symmetry/ordering,” “hoard-
ing,” “contamination/cleaning,” “aggression/checking” and
 “sexual/ religious obsessions.”32 A dimension was consid-
ered to be present if the patient reported either current or
lifetime history of at least 1 symptom included in the dimen-
sion. The Dimensional Y-BOCS (DY-BOCS)33 was used to 
assess the worst-ever severity of obsessive–compulsive
symptoms within each of these symptom dimensions; the
miscellaneous obsessions and compulsions dimension was
excluded from the analysis owing to its unspecificity.
SNP selection and genotyping
The GRIN2B gene is located in reverse orientation on chromo-
some 12p13.1, where it spans about 470 kb. Given its large
gen omic size and complex linkage disequilibrium structure,
complete tagging of the region exceeded the budgetary con-
straints of this study, so we decided to focus on genomic re-
gions previously reported to be associated with OCD, schizo-
phrenia or bipolar disorder, located at exon 13 and the 3′ UTR
of the GRIN2B gene.20,34 To select them, we downloaded the
genotyping data corresponding to the CEU trios (US residents
of northern and western European ancestry) of the HapMap
project (http ://hapmap .ncbi .nlm .nih .gov/; Data Release 24,
phaseII Nov08, on NCBI B36 assembly, dbSNP b126). Among
all available SNPs (n = 19), we selected the 12 variants with a
minor allele frequency higher than 0.01.
We typed SNPs using a custom VeraCode GoldenGate
Genotyping Assay (Illumina) according to the manufac-
turer’s protocols (www.illumina.com). Raw data were
processed using BeadStudio software (Illumina) to infer all
SNP genotypes via a genotyping cluster. For statistical analy-
sis, we selected those SNPs with a minimum genotyping rate
of 95%, and in Hardy–Weinberg equilibrium (p < 0.05);
10 SNPs among the 12 initial ones were finally included in
the analysis. The overall description of each polymorphism is
shown in Appendix 1, available at cma.ca/jpn.
Population admixture
The sample studied has been previously genotyped for popu-
lation admixture with anonymous unlinked SNPs and was
found to show no population stratification (for a detailed de-
scription, see Alonso and colleagues35).
Single SNP analysis
We assessed the significance of association between 10 SNPs
and affected status (cases versus controls) and between cases
according to each subphenotype (age at onset, comorbid tic dis-
order, contamination/cleaning, symmetry/ordering, hoarding,
sexual/religious and aggressive/checking) through multivari-
ate logistic regression assuming a codominant, dominant, reces-
sive and log-additive model of inheritance using the SNPassoc
R package.36 The models were adjusted using sex and age as co-
variates. Effect of genotype variants on symptom severity for
each DY-BOCS symptom dimension was assessed using analy-
sis of variance (ANOVA), with genotype as the factor variable
and scores on each symptom dimension as the dependent vari-
ables. To control for the possible confounding effect of depres-
sive comorbidity, we repeated all analyses excluding patients
with a comorbid affective disorder (n = 52). Bonferroni correc-
tion for 10 independent SNPs and the 7 different phenotypes
tested was used to estimate the significance of the results. Thus,
the statistical significance level was set at 0.003.
Haplotype analysis
The linkage disequilibrium pattern of the GRIN2B 3′ genomic
region was estimated through r2 and D’ values, and haplo-
type blocks were estimated from the 4 gamete rules as imple-
mented in Haploview software version 4.1.37 To perform the
haplotype-based association analysis with the block contain-
ing the significant SNP and the contamination phenotype, we
considered haplotypes with frequencies above 5%. Further-
more, to estimate the significance of the best results, we used
the permutation procedure (n = 1000). Analyses were per-
formed using Haploview software, and then the SNPassoc R




During the selection period, 262 outpatients were assessed by
the examiners and fulfilled DSM-IV criteria for OCD. Of
these, 11 were ruled out in accordance with the exclusion cri-
teria and 15 refused to take part in the study. In all, 236 con-
secutive white Spanish outpatients with OCD (125 men and
111 women) were included in the study. The control group
consisted of 296 unrelated participants recruited from a
group of healthy blood donors.
We submitted all 236 patients and 296 controls for geno-
typing. After the quality control assessments, the data avail-
able for all further analyses came from 225 patients and
279 controls. Of this sample for whom genotyping data were
available for analysis, the controls were older than patients
with OCD (mean age 40.02 [standard deviation (SD) 11.8],
range 18– 65 yr v. 34.0 [SD 10.5], range 18–63 yr; t = 6.2;
p < 0.001). There were no significant differences in sex distrib-
ution between the 2 groups (male:female ratio 161: 118 con-
trols v. 116:109 patients with OCD; χ2 = 1.1, p = 0.24).
Single SNP and haplotype association analysis
The complete list of the 10 tag SNPs used in the study, their chromosomal locations, allele
frequencies and genotyping rates are presented in Appendix 1. No significant difference in
the distribution of alleles or genotypes was detected between controls and patients with
OCD considered as a whole (data not shown). We further performed an analysis based on
the clinical presentation of OCD, considering age at onset, comorbid tic disorders and
symptom dimensions. For early onset OCD, comorbid tic disorders and symptom dimen-
sions, including symmetry/ordering, hoarding,  sexual/ religious and aggressive/checking,
no SNP achieved experiment-wide significance after adjustment for multiple testing. A sig-
nificant association was found between rs1805476 and the contamination/cleaning dimen-
sion (p = 0.002, 95% CI 1.37–4.22) under a dominant model, and this association remained
significant after multiple testing corrections (Table 1). The ANOVA test showed that pa-
tients carrying at least 1 T allele at this locus had significantly higher worst-ever scores on
the contamination/cleaning dimension of the DY-BOCS than those homozygous for the G
allele. No significant association was detected between scores on the other 
DY-BOCS symptom dimensions and rs1805476 variants (Table 2) or between the other
tested SNPs and DY-BOCS symptom dimension scores (data not shown).
We performed a further analysis stratified by sex and found that the association be-
tween this SNP and  contamination/ cleaning symptoms was significant only in male
patients (p < 0.001, 95% CI 1.77–9.65; Table 1). The same was true for the association be-
tween rs1805476 variants and DY-BOCS scores for each symptom dimension (Table 2).
For the haplotype analysis, we estimated the linkage disequilibrium pattern of the
region and identified 3 different blocks (Fig. 1). The significant SNP in the single SNP
analysis was in block 2 of 670 bp and contained 3 other SNPs (rs1805501, rs1805502 and
rs1805477). We performed the haplotype analysis of this block and found a significant
association between a composite A-A-T-C and the presence of contamination obses-
sions and cleaning compulsions (OR 1.92, 95% CI 1.22–3.01; permutation p = 0.023;
Table 3). No significant difference between male and female patients was detected for
the haplotype analysis when we corrected for sex.
To confirm that these genetic findings were not modulated by any other significant
clinical difference between patients with and without contamination/cleaning obses-
sions and compulsions, we compared the sociodemographic and clinical variables of
patients with OCD according to the presence of this symptom dimension. No signifi-
cant differences, including sex distribution, were detected between them except for the
DY-BOCS scores on the contamination/cleaning dimension (Table 4).
Results from our analysis considering only the patients without comorbid affective
disorders were not significantly different than those in the whole sample (data not
shown).
Discussion
Our study provides further evidence of a role for GRIN2B as a candidate gene for at least
certain OCD subphenotypes. Although we failed to replicate a global relation between
GRIN2B and OCD, on analyzing OCD subphenotypes and after correcting for multiple
comparisons, rs1805476 and a 4-SNP haplotype (rs1805476, rs1805477, rs1805501 and
rs1805502) were found to be associated with the presence of contamination obsessions
and cleaning compulsions. Our haplotype contained the 2-marker haplotype (rs1805476,
rs1805502) described by Arnold and colleagues20 in their initial analysis as associated
with OCD using a family-based association test.
Although none of the positive variants identified in this study had a direct func-
tional effect on the amino acid sequence of the protein, they might affect other regula-
tory aspects of GRIN2B expression, such as transcription, mRNA processing, nuclear
export or alteration of secondary structure. On the other hand, the variants detected in
our study may be in linkage disequilibrium with a functional variant located in non-
explored regions of GRIN2B. It has also been hypothesized that variants in the 3′ UTR
of some genes, like the ones explored in this study, may influence translational control
through alteration of binding sites for micro-RNAs, although direct evidence of such a
Alonso et al.
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Table 2: Effect of rs1805476 variants on DY-BOCS scores for symptom dimensions according to a dominant model
Patient group




checking Order/symmetry Sexual/religious Hoarding
All
GG 3.58 (5.1) 7.58 (5.0) 4.05 (5.5) 2.81 (5.0) 1.91 (3.8)
GT/TT 5.76 (5.4) 7.32 (4.6) 3.19 (5.1) 2.38 (4.5) 1.85 (3.6)
F 8.5 0.5 1.2 0.4 0.01
p value 0.004 0.46 0.26 0.51 0.92
Male
GG 2.38 (4.6) 7.71 (5.1) 3.48 (5.4) 3.04 (4.7) 2.62 (4.1)
GT/TT 5.56 (4.9) 7.74 (5.3) 3.95 (5.6) 2.59 (4.6) 2.23 (3.9)
F 10.7 0.001 0.1 0.2 0.2
p value 0.001 0.97 0.67 0.63 0.63
Female
GG 4.64 (5.4) 6.89 (4.8) 4.05 (5.5) 1.65 (4.1) 0.98 (2.7)
GT/TT 5.98 (5.9) 7.95 (4.7) 3.19 (5.1) 3.03 (4.7) 1.60 (3.7)
F 1.4 1.1 1.4 2.4 0.9
p value 0.23 0.27 0.26 0.12 0.34
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Fig. 1: Schematic representation of the GRIN2B gene structure. Black boxes indicate coding exons, open
boxes indicate first untranslated exons and the 3′ untranslated region. Haplotype blocks, linkage disequi-
librium structure and genotyped single nucleotide polymorphisms (SNPs) in the 3′ region of GRIN2B de-
rived by Haploview software. Alternate names for SNPs previously used in the literature are in parenthe-
ses. Linkage disequilibrium values are shown inside the squares if they are less than 1. The r2 linkage
disequilibrium colour scheme is as follows: r2 = 0: white; 0 < r2 < 1: shades of grey; r2 = 1: black.
role for the 3′ UTR in GRIN2B is not currently available.
Further research, including resequencing of GRIN2B, is
warranted to locate functional variants contributing to the
OCD phenotype as well as to identify mutant variants, mi-
crodeletions or duplications that might be involved in sus-
ceptibility to OCD.
Our results on symptom dimensions are especially rel -
evant given the current conceptualization of OCD as a multi-
dimensional disorder. The dissection of the OCD phenotype
into more homogeneous components has been proposed as a
way to improve our knowledge of the genetic factors impli-
cated in OCD.27 Early onset OCD, OCD with comorbid tic
disorders and OCD with associated sensory phenomena are
some of the subtypes more closely related to familial risk.
No significant association between these subphenotypes and
GRIN2B variants was detected in our sample. On the other
hand, the consideration of obsessive–compulsive symptom
dimensions, which have proven to be consistent, temporally
stable, valid and reliable constructs, has also provided
promising leads in recent genetic studies.38–42 Specific genetic
influences related to the contamination/cleaning dimension
in OCD have been postulated using twin data.43 Recent
neuro imaging studies suggest that this symptom dimension
may be mediated by a specific neural substrate, mainly com-
prising the insula;44 prefrontal cortical areas,45 such as the
ventromedial prefrontal regions including the anterior cin-
gulate, orbitofrontal gyri and ventrolateral prefrontal cor-
tex;46 and the caudate nucleus.46,47 Arnold and colleagues48 re-
cently reported the association between the C-C haplotype
of rs1805476 and decreased left orbitofrontal cortex volume
and right anterior cingulate volume compared with carriers
of the A allele in a sample of pediatric patients with OCD.
The same authors also described a significant association be-
tween anterior cingulate glutamatergic concentration and
the GRIN2B rs1019385 polymorphism.49 The particular im -
plication of ventromedial regions in the development of
 contamination/ cleaning symptoms may explain the specific
contribution of GRIN2B to the genetic susceptibility to this
symptom dimension.
Our group has recently reported on the positive associa-
tion between the contamination/cleaning symptom dimen-
sion and another candidate gene, the estrogen receptor α
gene (ESR1).35 The NMDA receptors have been hypothesized
as possible mediators of estrogen actions in the brain. Fluctu-
ations in hippocampal dendritic spine density related to
estradiol action during the estrous cycle have been shown to
occur via a mechanism requiring NMDA receptor activa-
tion.50 Moreover, animal studies have shown that expression
of the NMDA receptor R2B gene is regulated by estrogen and
that the NMDA receptor containing the R2B subunit may be
involved in the initiation of puberty.51 We explored whether a
gene × gene interaction between GRIN2B and ESR1 might
contribute to genetic susceptibility to  contamination/
cleaning symptoms in OCD but failed to detect this interac-
tion in our sample. The 3′ UTR of the human NR2D subunit
of the NMDAR gene has been reported to contain at least
4 half palindromic estrogen responsive elements.52 The possi-
bility that susceptibility to the contamination/cleaning symp-
tom dimension might be modulated by the interaction be-
tween ESR1 and NMDA receptor genes other than GRIN2B
should be further explored.
Genetic variations of GRIN2B have been implicated in the
genetic susceptibility to neuropsychiatric disorders other
than OCD, including attention-deficit/hyperactivity disor-
der,53 dyslexia,54 schizophrenia and bipolar disorder (for a re-
view, see Cherlyn and colleagues34). Moreover, Parkinson
disease and Huntington disease, 2 neurologic conditions in
which obsessive–compulsive symptoms are not rare, have
also been associated with changes in the function of the
NR2B-containing NMDA receptors (for a review, see Loftis
and Janowsky22).
As in the case of SLC1A1,12–14 the association between
rs1805476 and OCD was detected in male but not female
patients. Several studies have reported sex-related differ-
ences in the clinical manifestations of OCD, including an
earlier age at onset for male patients,55–58 more cleaning ob-
sessions and contamination compulsions in female patients
and  symmetry/ ordering symptoms in male patients,58–60
and sex differences in response to OCD treatment.61 More-
over a sex-specific contribution to OCD susceptibility has
also been reported for other candidate genes, such as MAO
and COMT.58
Limitations
The major limitation of our study is the potential susceptibil-
ity of the case–control design to population stratification
 owing to admixture of different ethnicities among patients
versus controls. We addressed this issue by genotyping multi-
ple  ancestry-informative markers and identified only 1 popu-
lation stratum among patients and controls. Nevertheless, the
Caucasian origin of all the participants cannot be conclusively
Alonso et al.
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A A G C 45.7 39.8 51.0 1.0 — —
A A T C 36.4 30.8 42.6 1.92 (1.22–3.01) 0.0047 0.023
A G G C 16.2 16.7 15.7 1.23 (0.72–2.09 0.45 —
CI = confidence interval; OR = odds ratio.
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assigned, and subtle or weak admixtures may not have been
identified. Furthermore, the use of psychiatrically unscreened
blood donors as the control group was not optimal, but could
be considered potentially cost-effective and had a negligible
effect on statistical power in the study of a disorder such as
OCD with a population lifetime risk of 1%–2%.62 The small
sample size of some OCD subphenotypes (particularly pa-
tients with sexual/religious and hoarding symptoms) may
have limited our ability to detect subtle genetic contributions
in these subgroups. Finally, we tested polymorphisms located
in the 3′ UTR and exon 13 of GRIN2B, so it is possible that we
missed other areas of the gene that could be associated with
OCD. Future studies should employ a more comprehensive
approach to explore the implication of other GRIN2B variants
in the susceptibility to OCD.
Conclusion
We identified a positive association between GRIN2B vari-
ants and certain subphenotypes of OCD. This evidence con-
verges with recent bioinformatic approaches suggesting the
involvement of GRIN2B and its interaction with other gluta-
matergic and dopaminergic genes in a gene pathway under-
lying OCD pathogenesis.63 If confirmed, these findings argue
Table 4: Sociodemographic and clinical characteristics of the 225 patients with obsessive–compulsive
disorder with and without contamination/cleaning obsessions and cleaning compulsions
Characteristic






n = 117 t/χ2 p value
Age, yr 34.7 (10.2) [18–63] 33.3 (10.2) [18–65] –0.9 0.32
Male:female 55:53 62:55 1.07 0.73
Years of education 11.9 (3.6) 12.0 (3.8) –0.5 0.61
Age at onset of OCD, yr 18.8 (8.5) 20.6 (8.0) 1.6 0.10
Onset before 15, no. (%) 44 (40.7) 32 (27.3) 4.1 0.06
Basal Y-BOCS score
Global 26.8 (5.9) 26.3 (5.9) –0.6 0.63
Obsessions 13.4 (3.0) 13.4 (2.9) –0.02 0.97
Compulsions 13.3 (3.0) 12.9 (3.6) –1.0 0.28
Basal HAM-D score 13.2 (4.8) 13.5 (6.2) 0.4 0.56
DY-BOCS score
Aggressive/checking 6.7 (5.0) 8.2 (4.8) 2.1 0.034
Contamination/cleaning 10.3 (2.4) 0.1 (1.2) –39.0 0.001
Sexual/religious 2.3 (4.2) 2.7 (4.8) 0.6 0.52
Hoarding 1.9 (3.6) 1.7 (3.7) –0.3 0.73
Symmetry/ordering 3.5 (5.1) 3.4 (5.5) –0.07 0.91
Comorbid diagnosis, no. (%)
Any comorbid diagnosis 49 (45.3) 55 (47.0) 0.05 0.32
Affective disorders 24 (22.2) 28 (23.9) 0.05 0.32
Major depressive disorder 16 18
Dysthymia 4 5
Depressive disorder NEC 2 3
Bipolar disorder 2 2
Anxiety disorders other than OCD 19 (17.5.) 21 (17.9) 0.6 0.41
Tics disorder or GT 15 (13.8) 16 (13.6) 0.9 0.55
Eating disorders 7 (6.4) 8 (6.8) 0.01 0.36
Symptom dimensions present, no. (%)
Aggressive/checking 69 (63.8) 87 (74.3) 3.4 0.17
Sexual/religious 22 (20.3) 31 (26.4) 2.0 0.32
Hoarding 27 (25.0) 32 (27.3) 1.0 0.52
Symmetry/ordering 46 (42.5) 35 (29.9) 5.0 0.07
Psychiatric family history, no. (%)
Any psychiatric diagnosis 54 (51.4) 63 (53.8) 0.07 0.31
OCD 21 (20.0) 20 (17.0) 0.09 0.27
Anxiety disorders other than OCD 15 (14.2) 17 (14.5) 0.6 0.44
Affective disorders 24 (22.8) 27 (23.0) 0.1 0.35
Tic disorders or GT 10 (9.5) 17 (14.5) 0.06 0.23
DY-BOCS = Dimensional Yale–Brown Obsessive Compulsive Scale;33 GT = Gilles de la Tourette syndrome; HAM-D = Hamilton Rating
Scale for Depression;31 NEC = not elsewhere classified; OCD = obsessive–compulsive disorder; Y-BOCS = Yale–Brown Obsessive–
Compulsive Scale.30
*Unless otherwise indicated.
in favour of testing new glutamate modulating agents as po-
tential therapeutic alternatives in patients with refractory
OCD, especially in certain subphenotypes.
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